Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p.

Marchesi, F., Salmanton-García, J., Emarah, Z., Piukovics, K., Nucci, M., López-García, A., et al. (2022). COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA). HAEMATOLOGICA [10.3324/haematol.2022.280847].

COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)

Del Principe, Maria Ilaria;
2022

Abstract

Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p.
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15
English
Marchesi, F., Salmanton-García, J., Emarah, Z., Piukovics, K., Nucci, M., López-García, A., et al. (2022). COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA). HAEMATOLOGICA [10.3324/haematol.2022.280847].
Marchesi, F; Salmanton-García, J; Emarah, Z; Piukovics, K; Nucci, M; López-García, A; Ráčil, Z; Farina, F; Popova, M; Zompi, S; Audisio, E; Ledoux, M; Verga, L; Weinbergerová, B; Szotkovski, T; Da Silva, Mg; Fracchiolla, N; De Jonge, N; Collins, G; Marchetti, M; Magliano, G; García-Vidal, C; Biernat, Mm; Van Doesum, J; Machado, M; Demirkan, F; Al-Khabori, M; Žák, P; Víšek, B; Stoma, I; Méndez, G; Maertens, J; Khanna, N; Espigado, I; Dragonetti, G; Fianchi, L; Del Principe, Mi; Cabirta, A; Ormazabal-Vélez, I; Jaksic, O; Buquicchio, C; Bonuomo, V; Batinić, J; Omrani, As; Lamure, S; Finizio, O; Fernández, N; Falces-Romero, I; Blennow, O; Bergantim, R; Ali, N; Win, S; Van Praet, J; Tisi, Mc; Shirinova, A; Schönlein, M; Prattes, J; Piedimonte, M; Petzer, V; Navrátil, M; Kulasekararaj, A; Jindra, P; Sramek, J; Glenthøj, A; Fazzi, R; De Ramón-Sánchez, C; Cattaneo, C; Calbacho, M; Bahr, Nc; El-Ashwah, S; Cordoba, R; Hanakova, M; Zambrotta, G; Sciumè, M; Booth, S; Rodrigues, Rn; Sacchi, Mv; García-Poutón, N; Martín-González, J; Khostelidi, S; Gräfe, S; Rahimli, L; Ammatuna, E; Busca, A; Corradini, P; Hoenigl, M; Klimko, N; Koehler, P; Pagliuca, A; Passamonti, F; Cornely, Oa; Pagano, L
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Marchesi 2022.pdf

accesso solo dalla rete interna

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 3.65 MB
Formato Adobe PDF
3.65 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/306856
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact